Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.75 |
| ▸ | CDK2 | P24941 | 13/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.69 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.69 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.69 |
| ▸ | CDK9 | P50750 | 7/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.69 |
| ▸ | GSK3A | P49840 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.68 |
| ▸ | CCNK | O75909 | 2/20 | 0.68 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.68 |
| ▸ | CDK4 | P11802 | 1/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.68 |
| ▸ | CCND1 | P24385 | 1/20 | 0.68 |
| ▸ | CDK7 | P50613 | 1/20 | 0.68 |
| ▸ | CCNH | P51946 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17628615 | 0.89 | CDK1 (0.87) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL25299779 | 0.87 | CDK1 (0.62) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL1400442 | 0.86 | CDK1 (1.00) | CDK1CDK2CDK5DYRK1ACDK9 | |
| SCHEMBL15372679 | 0.85 | CDK2 (0.78) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL30332211 | 0.84 | CDK1 (0.66) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL6152647 | 0.84 | CDK1 (0.82) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL7889584 | 0.84 | CDK2 (0.82) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL27144163 | 0.83 | CDK1 (0.74) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL25308752 | 0.83 | CCNK (0.68) | CDK1CDK2CCNA2CCNA1CDK5 | |
| SCHEMBL3507625 | 0.83 | DYRK1A (0.68) | CDK1CDK2CCNA2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023059609-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-2187889-B1 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NAT RECH SCIENT (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-8431583-B2 | Use of purine derivatives for the manufacture of a medicament | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-04-30 | — | — | US | disclosed |
| US-8431583-B2 | Use of purine derivatives for the manufacture of a medicament | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-04-30 | — | — | US | disclosed |
| US-20100311768-A1 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-09 | — | — | US | disclosed |
| US-20100311768-A1 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-09 | — | — | US | disclosed |
| WO-2010103473-A1 | METHOD OF TREATMENT OF POLYCYSTIC DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA | CHU DE BREST (FR) | 2010-09-16 | — | — | WO | disclosed |
| EP-2187889-A2 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | Centre National De La Recherche Scientifique (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009068761-A2 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068761-A2 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | CDK1 20/4885CDK2 88/4885CCNA2 802/4885 |
| US-20100311768-A1 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | ENTPD5, HPRT1, P2RY1 | CDK1 361/4885CDK2 942/4885CCNA2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.